These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29971600)

  • 61. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.
    Hiremath P; Lawler PR; Ho JE; Correia AW; Abbasi SA; Kwong RY; Jerosch-Herold M; Ho CY; Cheng S
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623770
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors.
    Maron BJ; Maron MS; Semsarian C
    Heart Rhythm; 2012 Jan; 9(1):57-63. PubMed ID: 21839045
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes.
    Jääskeläinen P; Miettinen R; Kärkkäinen P; Toivonen L; Laakso M; Kuusisto J
    Ann Med; 2004; 36(1):23-32. PubMed ID: 15000344
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The genetic basis of hypertrophic cardiomyopathy in cats and humans.
    Kittleson MD; Meurs KM; Harris SP
    J Vet Cardiol; 2015 Dec; 17 Suppl 1(Suppl 1):S53-73. PubMed ID: 26776594
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic, clinical, molecular, and pathogenic aspects of the South Asian-specific polymorphic MYBPC3
    Arif M; Nabavizadeh P; Song T; Desai D; Singh R; Bazrafshan S; Kumar M; Wang Y; Gilbert RJ; Dhandapany PS; Becker RC; Kranias EG; Sadayappan S
    Biophys Rev; 2020 Aug; 12(4):1065-1084. PubMed ID: 32656747
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment.
    Ramaraj R
    Cardiol Rev; 2008; 16(4):172-80. PubMed ID: 18562807
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy.
    Erdmann J; Daehmlow S; Wischke S; Senyuva M; Werner U; Raible J; Tanis N; Dyachenko S; Hummel M; Hetzer R; Regitz-Zagrosek V
    Clin Genet; 2003 Oct; 64(4):339-49. PubMed ID: 12974739
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
    Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
    J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure.
    Waldmüller S; Erdmann J; Binner P; Gelbrich G; Pankuweit S; Geier C; Timmermann B; Haremza J; Perrot A; Scheer S; Wachter R; Schulze-Waltrup N; Dermintzoglou A; Schönberger J; Zeh W; Jurmann B; Brodherr T; Börgel J; Farr M; Milting H; Blankenfeldt W; Reinhardt R; Özcelik C; Osterziel KJ; Loeffler M; Maisch B; Regitz-Zagrosek V; Schunkert H; Scheffold T;
    Eur J Heart Fail; 2011 Nov; 13(11):1185-92. PubMed ID: 21750094
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification of a novel MYBPC3 gene variant in a patient with hypertrophic cardiomyopathy.
    Brion M; Allegue C; Gil R; Blanco-Verea A; Carracedo A; Pagannone E; Evangelista A; Di Castro S; Marchitti S; Stanzione R; Volpe M; Rubattu S
    Ann Clin Lab Sci; 2010; 40(3):285-9. PubMed ID: 20689143
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
    Ho CY; McMurray JJV; Cirino AL; Colan SD; Day SM; Desai AS; Lipshultz SE; MacRae CA; Shi L; Solomon SD; Orav EJ; Braunwald E;
    Am Heart J; 2017 May; 187():145-155. PubMed ID: 28454798
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Key Value of RNA Analysis of MYBPC3 Splice-Site Variants in Hypertrophic Cardiomyopathy.
    Singer ES; Ingles J; Semsarian C; Bagnall RD
    Circ Genom Precis Med; 2019 Jan; 12(1):e002368. PubMed ID: 30645170
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Mutations in genes for sarcomeric proteins].
    Kimura A
    Nihon Rinsho; 2000 Jan; 58(1):117-22. PubMed ID: 10885298
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy.
    Núñez L; Gimeno-Blanes JR; Rodríguez-García MI; Monserrat L; Zorio E; Coats C; McGregor CG; Hernandez del Rincón JP; Castro-Beiras A; Hermida-Prieto M
    Circ J; 2013; 77(9):2358-65. PubMed ID: 23782526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
    Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
    Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A heterozygous MYBPC3 (c. 772+1G > A) mutant human induced pluripotent stem cell line (ZZUNEUi025-A) generated from a male patient with hypertrophic cardiomyopathy.
    Zhao X; Cao J; Li X; Liu M; Liu Y; Dong J; Zhao X
    Stem Cell Res; 2022 Apr; 60():102722. PubMed ID: 35257994
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives.
    Zampieri M; Berteotti M; Ferrantini C; Tassetti L; Gabriele M; Tomberli B; Castelli G; Cappelli F; Stefàno P; Marchionni N; Coppini R; Olivotto I
    Curr Heart Fail Rep; 2021 Aug; 18(4):169-179. PubMed ID: 34148184
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hypertrophic cardiomyopathy: a heart in need of an energy bar?
    Vakrou S; Abraham MR
    Front Physiol; 2014; 5():309. PubMed ID: 25191275
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An induced pluripotent stem cell line (EHTJUi003-A) generated from a neonate with c.1377delC mutation in the gene MYBPC3 causing hypertrophic cardiomyopathy.
    Jia WW; Lu JZ; Zhang L; Cao HX; Qi YY; Zhu HY; Bai ZH; Zhang SM; Qiao ZB; Bao Y; Liu ZM
    Stem Cell Res; 2021 May; 53():102328. PubMed ID: 34087980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.